Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion results with or without the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors
    Meeting Abstract

    Drilon, A.; Garralda, E.; Stathis, A.; Szyldergemajn, S.; Hyman, D.; Boni, V.; Griguolo, G.; Martinez, E. J.; Makker, V.; Canziani, L.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer
    Meeting Abstract

    Forde, P. M.; Smith, K. N.; Chaft, J. E.; Hellmann, M.; Merghoub, T.; Wolchok, J. D.; Yang, S. C.; Battafarano, R. J.; Gabrielson, E.; Georgiades, C. S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A phase 2, fast real-time assessment of combination therapies in immuno-oncology trial in patients with advanced non-small cell lung cancer (FRACTION-lung)
    Meeting Abstract

    Fracasso, P. M.; Freeman, D. J.; Simonsen, K.; Shen, Y.; Gupta, M.; Comprelli, A.; Gainor, J. F.; Hellmann, M.; Chow, L. Q.; Forde, P. M.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy
    Meeting Abstract

    Chu, Q. S. C.; Markman, B.; Leighl, N.; Krug, L.; Rudin, C.; Lathers, D.; Basciano, P.; Fracasso, P. M.; Kollia, G.; Phillips, P.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Long-term outcomes with nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced (adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update
    Meeting Abstract

    Barlesi, F.; Steins, M.; Horn, L.; Ready, N.; Felip, E.; Borghaei, H.; Spigel, D. R.; Arrieta, O.; Antonia, S. J.; Fayette, J.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC
    Meeting Abstract

    Ma, B. B. Y.; Rudin, C. M.; Cervantes, A.; Dowlati, A.; Costa, D.; Schmid, P.; Heist, R.; Villaflor, V. M.; Sarkar, I.; Huseni, M. A.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Something old, something new, something borrowed, something fused: Novel EGFR rearrangements in lung adenocarcinomas
    Journal Article

    Paik, P. K.
    Cancer Discovery (2016)

    Fulltext@MSK | Save
  • The type II switch control kinase inhibitor, DCC-2701 (altiratinib) effectively inhibits resistant NTRK kinase domain mutants
    Meeting Abstract

    Drilon, A.; Hofmann, N.; Flynn, D.; Smith, B.; Davare, M.
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors
    Meeting Abstract

    Drilon, A.; Marwan, F.; Fu, S.; Patel, M. R.; Olszanski, A. J.; Lockhart, A. C.; Liu, S. V.; Bazhenova, L.; Seery, T.; Nikolinakos, P.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Delayed 18F-FDG PET imaging can improve detection of lesions in patients with advanced non-small cell lung cancer
    Meeting Abstract

    Krebs, S.; Dunphy, M.; Humm, J.; Chaft, J.; Fredrickson, J.; Weber, W. A.
    European Journal of Nuclear Medicine and Molecular Imaging (2016)

    Fulltext@MSK | Save